BET bromodomain proteins are required for glioblastoma cell proliferation
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2014/02/19
-
Journal
-
Indian UGC (journal)
-
Refrences30
-
Citations104
-
Chiara Pastori
-
Mark Daniel
-
Clara Penas
-
Claude-Henry Volmar
-
Andrea L Johnstone
-
Shaun P Brothers
-
Regina M Graham
-
Bryce Allen
-
Jann N Sarkaria
-
Ricardo J Komotar
-
Claes Wahlestedt
-
Nagi G Ayad
Cite
Pastori, Chiara, et al. “BET Bromodomain Proteins Are Required for Glioblastoma Cell Proliferation”. Epigenetics, vol. 9, no. 4, 2014, pp. 611-20, https://doi.org/10.4161/epi.27906.
Pastori, C., Daniel, M., Penas, C., Volmar, C.-H., Johnstone, A. L., Brothers, S. P., Graham, R. M., Allen, B., Sarkaria, J. N., Komotar, R. J., Wahlestedt, C., & Ayad, N. G. (2014). BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics, 9(4), 611-620. https://doi.org/10.4161/epi.27906
Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics. 2014;9(4):611-20.
Journal Categories
Science
Biology (General)
Science
Biology (General)
Genetics
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Title | 1995 | |||
Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery | Current Protocols in Pharmacology | 104 | 2011 | |
| BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc | Cell |
| 2,120 | 2011 |
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Nature |
| 1,423 | 2011 |
| 10.1038/nature09589 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine | Cell Death Discovery |
| 1 | 2024 |
RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma | Scientific Reports |
| 2024 | |
MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma | BMC Cancer |
| 2024 | |
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks | Journal of Experimental & Clinical Cancer Research |
| 1 | 2024 |
| Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer | Bioorganic Chemistry |
| 1 | 2023 |
Citations Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 34
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Identifying Glioblastoma Gene Networks Based on Hypergeometric Test Analysis and was published in 2014. The most recent citation comes from a 2024 study titled RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma. This article reached its peak citation in 2017, with 14 citations. It has been cited in 74 different journals, 36% of which are open access. Among related journals, the Cancers cited this research the most, with 4 citations. The chart below illustrates the annual citation trends for this article.